FTHL17

Across TCGA pan-cancer cohorts, FTHL17 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FTHL17’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where FTHL17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FTHL17 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

UCEC, LUAD, and LUSC are the cancer types where FTHL17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTHL17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	IV	+0.250	.014	2	view →
LUAD	All	All	+0.333	.047	1	view →
LUSC	All	All	+0.269	.046	1	view →
KIRC	All	All	−0.003	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

FTHL17–UCEC

Open the UCEC breakdown →